Natural history of familial cerebral cavernous malformations: the CCM_Italia cohort study

Read full text
Authors: Silvia Lanfranconi, Elisa Scola, Deborah Novelli, Anna Poggesi, Francesca Pescini, Marco Pavanello, Ferruccio Romano, Quintino Giorgio D’Alessandris, Walter Marani, Francesco Signorelli, Giorgio İaconetta, Giovanni Fernando Torelli
+23 more Enrico Fainardi, Mariasavina Severino, Luigi Gianmaria Remore, Giulio Bertani, Giorgio Conte, Valeria Capra, Antonella Vasamì, Enrico Nicolis, Giorgia Contino, DARIO GERVÁSIO RONCHI, Maria Chiara Palmieri, Alessandra Previtali, Pier Paolo Mattogno, Carmelo Lucio Sturiale, Maria Elena Solarino, Rita Caliulo, Maria Teresa Bozzi, F. Fratini, Elisa Roncati Zanier, Roberto Latini, Jennifer Marie Theresia Anna Meessen, Marco Locatelli, and the CCM_Italia investigators
Cited by: 1
References: 8

Abstract

Background: Familial cerebral cavernous malformations (fCCMs) are a rare genetic autosomal dominant cerebrovascular disease characterized by multiple cerebral and spinal angiomas. The condition is caused by mutations in KRIT1 (CCM1), CCM2 (malcavernin), or PDCD10 (CCM3) and may lead to intracerebral hemorrhage (ICH) or non-hemorrhagic focal neurological deficits (FNDs), potentially leading to severe disability and even death. To date, little is known about disease progression, and tools to identify patients at higher risk are lacking. Methods: Pediatric and adult fCCM patients, whether symptomatic or asymptomatic, will be enrolled and followed annually over a 2-year period. Participants will undergo clinical assessments, blood sampling, and 3 T brain MRI scans at baseline, 12 months, and 24 months. The primary outcome is the new occurrence of symptomatic ICH or FNDs attributable to CCMs over 24 months. Patient characteristics will be assessed for the primary and secondary endpoints and illustrated using Kaplan-Meier curves and Cox proportional hazard regressions. This trial is registered with ClinicalTrials.gov, NCT06983132 and is currently recruiting participants. Discussion/conclusion: Despite increasing efforts in basic and clinical research and an improved understanding of the pathogenic mechanisms underlying fCCM, tools to predict disease progression, identify at-risk individuals, and pinpoint effective therapeutic targets are still lacking. This study aims to create the largest Italian cohort of fCCM patients, who will be monitored closely over time to collect data that may help identify risk factors and disease trajectories. The collection of standardized information on clinical and radiological evolution, along with results from circulating biomarkers, will help address the complexities of the disease and may suggest potential reliable markers of disease progression. Clinical trial registration: ClinicalTrials.gov, identifier NCT06983132.

Fields of Study & Subjects

Vascular Malformations Diagnosis and Treatment Vascular Malformations and Hemangiomas Intracerebral and Subarachnoid Hemorrhage Research

Publication details

Journal / source
Frontiers in Neurology
Publisher
Frontiers Media SA
Volume
16
Pages
1668098–1668098
Publication date
5 January 2026
Language
EN